Vitamin D supplementation for cystic fibrosis

Ferguson, Janet H. and Chang, Anne B. (2012) Vitamin D supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews, 4: 1-29. doi:10.1002/14651858.CD007298.pub3

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Ferguson, Janet H.
Chang, Anne B.
Title Vitamin D supplementation for cystic fibrosis
Journal name Cochrane Database of Systematic Reviews   Check publisher's open access policy
ISSN 1469-493X
Publication date 2012-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1002/14651858.CD007298.pub3
Open Access Status
Issue 4
Start page 1
End page 29
Total pages 29
Place of publication Oxford,U.K.
Publisher John Wiley & Sons
Collection year 2013
Language eng
Formatted abstract
Background
Cystic fibrosis (CF) is a genetic disorder with multiorgan effects. In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins (A, D, E, K) may occur. Vitamin D is involved in calcium homeostasis and bone mineralisation and may have extraskeletal effects. This review examines the evidence for vitamin D supplementation in CF.

Objectives

To assess the effects of vitamin D supplementation on the frequency of vitamin D deficiency, respiratory outcomes and vitamin D toxicity in the CF population.

Search methods

We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Most recent search: 15 February 2012.

Selection criteria

Randomised and quasi-randomised controlled trials of vitamin D supplementation compared to placebo in the CF population regardless of exocrine pancreatic function.

Data collection and analysis

Both authors independently assessed the 'risk of bias' of each included trial and extracted outcome data (from published trial information) for assessment of bone mineralization, growth and nutritional status, frequency of vitamin D deficiency, respiratory status, quality of life and adverse events.

Main results

Three studies are included, although only data from two were available (41 adults and children with CF). One of these studies compared supplemental 800 international units (IU) vitamin D and placebo for 12 months in 30 osteopenic pancreatic insufficient adults; both groups continued 900 IU vitamin D daily. The other (abstract only) compared supplemental 1g calcium alone, 1600 IU vitamin D alone, 1600 IU vitamin D and 1g calcium and placebo in a double-blind randomised cross-over trial; only 11 children (vitamin D and placebo groups) after six-months supplementation are included; inclusion criteria, pancreatic sufficiency or disease status of participants are not defined. There were no significant differences in primary or secondary outcomes in either study. The studies are not directly comparable due to differences in supplementation, outcome reporting and possibly participant characteristics (eg severity of lung disease, growth and nutrition, pancreatic sufficiency). There were no adverse events in either study. The third study (abstract only) compared daily calcitriol (0.25 or 0.5 micrograms) with placebo in pancreatic insufficient children and young adults, only pre-intervention data were available.

Authors' conclusions

There is no evidence of benefit or harm in the limited number of small-sized published trials. Adherence to relevant CF guidelines on vitamin D should be considered until further evidence is available.
Keyword Bone Density Conservation Agents [administration & dosage; adverse effects]
Bone Diseases, Metabolic [drug therapy; etiology]
Calcitriol [administration & dosage; adverse effects]
Cystic Fibrosis [complications]
Dietary Supplements
Exocrine Pancreatic Insufficiency [complications]
Randomized Controlled Trials as Topic
Vitamin D [administration & dosage; adverse effects]
Vitamin D Deficiency [complications; drug therapy]
Adult
Child
Humans
Pulmonary-Function
Efficacy
Health
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Faculty of Health and Behavioural Sciences -- Publications
Official 2013 Collection
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Mon, 13 May 2013, 14:11:11 EST by Matthew Lamb on behalf of School of Medicine